Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises

Area of Science:

• Hepatology
• Oncology
• Immunology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• HCC exhibits significant resistance to conventional therapies.
• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), offers a novel therapeutic strategy.

Purpose of the Study:

• To review the concepts and potential of immunotherapy for HCC treatment.
• To elucidate the mechanisms of immunotherapy in the context of HCC.
• To evaluate pre-clinical and clinical insights into immunotherapy for HCC.

Main Methods:

• Comprehensive review of pre-clinical and clinical studies on HCC immunotherapy.
• Analysis of the tumor microenvironment (TME) and immune evasion mechanisms in HCC.
• Evaluation of current immunotherapeutic approaches and their clinical applications.

Main Results:

• Immunotherapy, including ICIs, demonstrates significant potential in enhancing patient outcomes for HCC.
• Understanding TME and immune evasion is crucial for designing effective immunotherapeutic strategies.
• Recent clinical trials show promising efficacy and safety profiles for immunotherapy drugs in HCC.

Conclusions:

• Immunotherapy represents a significant advancement in HCC treatment, offering new hope for patients.
• Addressing immune evasion and resistance is key to maximizing immunotherapy's potential.
• Combination therapies may further improve treatment efficacy in HCC.